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Abstract
Background In men, the long-term consequences of low serum levels of sex steroids, vitamin D metabolites, and insulin-like
growth factor 1 (IGF-1) on the evolution of muscle mass, muscle strength, or physical performance are unclear. Moreover,
there are no data about the relationship between these hormones and incident sarcopenia defined as low muscle mass
and function. The aim of this study was to determine whether the baseline levels of sex hormones, vitamin D metabolites,
and IGF-1 predict changes in muscle mass, muscle strength, physical performance, and incident sarcopenia.
Methods In 518 men aged 40–79 years, recruited for participation in the European Male Ageing Study, total, free, and
bioavailable testosterone (T), oestradiol (E), sex hormone-binding globulin, IGF-1, 25-hydroxyvitamin D (25OHD), 1,25-
dihydroxyvitamin D (1,25(OH)2D), and parathyroid hormone were assessed at baseline. Appendicular lean mass (aLM), gait
speed, and grip strength were measured at baseline and after a mean follow-up of 4.3 years. Sarcopenia was defined by
the definition of Baumgartner (relative aLM ≤7.26 kg/m2), the International Working Group on Sarcopenia (IWGS), and the
European Working Group on Sarcopenia in Older People (EWGSOP).
Results aLM significantly decreased from age 50years, while gait speed and grip strength significantly decreased from age 70years.
The incidence of sarcopenia by the definitions of Baumgartner, IWGS, and EWGSOP was 8.1%, 3.0%, and 1.6%, respectively. After
adjustment for age, centre, body mass index, smoking, and number of comorbidities at baseline, baseline levels of T and vitamin D
metabolites were not associated with change in aLM, gait speed, and/or grip strength, while a high baseline level of total E2 was
associated with a greater decrease in aLM. In men aged ≥70years, low IGF-1 was associated with a greater decrease in gait speed.
Baseline endocrine variables were not independently associated with an increased risk of incident sarcopenia by any definition.
Conclusions Low levels of T and 25OHD do not predict loss of muscle mass, gait speed, or grip strength in middle-aged and
elderly community-dwelling European men. Low IGF-1 predicts change in gait speed in men aged ≥70 years.
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Introduction
Loss of muscle mass and strength is a key feature of the age-
ing process that predisposes to disability, limited mobility,
falls, fractures, and death.1 In 1989, Rosenberg introduced
the term sarcopenia to describe the age-related loss of
muscle mass.2 A consensus on the concept of sarcopenia is
however still lacking. Currently, some expert groups use the
term sarcopenia to indicate the age-related loss of muscle
mass and strength, while other authors suggest to confine
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sarcopenia to its original meaning of loss of muscle mass and
have introduced the term dynapenia to describe the age-
related loss of muscle strength.3 Accordingly, the operational
definition of sarcopenia varies from low relative appendicular
skeletal muscle mass (RASM)4 to definitions that add muscle
strength and/or physical performance.1,5–8 Recently, the
Foundation for the National Institutes of Health Sarcopenia
Project proposed operational criteria for sarcopenia with
evidence-based cutpoints for low muscle mass, weakness,
and slowness.8
Several techniques exist to measure muscle mass, muscle
strength, and physical performance. Computed tomography
(CT) and magnetic resonance imaging are gold standards to
measure muscle mass, but their use is restricted to research
purposes because of high cost, limited availability, and in
the case of CT, radiation exposure.1 Dual-energy X-ray
absorptiometry (DXA) is one of the alternative methods to
assess muscle mass in research and clinical settings, although
its availability and use in clinical practice are still not very
broad.1,9 Several longitudinal studies have reported age-
related changes in muscle mass using DXA, but mainly in
the elderly.10,11 We are aware of only one study that has
described the 6-year change in muscle mass in middle-aged
Japanese men and women.12 Similarly, most longitudinal
studies that have examined the age-related decline in muscle
strength include elderly individuals,13 with few data in
middle-aged persons separately (<60 years).14
Low serum levels of sex steroids, in particular testosterone
(T), as well as 25-hydroxyvitamin D (25OHD) and insulin-like
growth factor 1 (IGF-1) have been considered to be potential
risk factors for sarcopenia since these hormones are involved
in the proliferation and myogenic differentiation of satellite
cells and promote muscle protein synthesis.15 1,25-
dihydroxyvitamin D (1,25(OH)2D), the active metabolite of
25OHD, also regulates the synthesis of proteins that influence
calcium transport and muscle contractility, and vitamin D
status also affects inflammation as well as insulin secretion
and sensitivity, all factors that have been linked to sarco-
penia.15,16 However, longitudinal studies about the associa-
tion between these anabolic hormones and changes in
either muscle mass, muscle strength, or physical performance
are scanty and conflicting. In most male or mixed cohorts,
low serum levels of total, free, and/or bioavailable T were
associated with loss of muscle mass17,18 but not muscle
strength17,19–21 over a 2 to 10-year follow-up. The association
between T and change in physical performance was less
consistent, with no association with total T unless in men
who experienced weight loss17,19,20 and inconsistent results
for free T.19,20 Less is known about the longitudinal associa-
tions between oestradiol (E2) or sex hormone-binding globu-
lin (SHBG) and change in muscle mass, strength, or physical
performance,17,19,21 and prospective studies exploring the
relationship with vitamin D metabolites have reported incon-
sistent results for 25OHD and are lacking for 1,25(OH)2D. In
some cohorts, low baseline 25OHD was associated with loss
of muscle strength and/or decline in physical perfor-
mance,22–24 but in others, this association was not ob-
served.25,26 Low 25OHD was not associated with a significant
change in muscle mass, but this has been scantily investi-
gated.22,24 There are to date, to our knowledge, no pro-
spective data looking at the association between these
hormones and sarcopenia defined by low muscle mass and
low muscle function. The Longitudinal Ageing Study
Amsterdam (LASA) is the only prospective study that has
investigated the association between low 25OHD and a
threshold level of loss of muscle mass or strength, thus inci-
dent sarcopenia.22 Other, cross-sectional, studies that have
examined the association between 25OHD and prevalent
sarcopenia found significantly lower 25OHD in subjects with
low muscle mass27,28 although in one of these not in men.28
The aim of our study was to determine in a prospective
cohort of middle-aged and elderly men (i) changes in muscle
mass, muscle strength, and physical performance; (ii)
whether any change can be predicted by baseline levels of
sex hormones, vitamin D metabolites, and IGF-1; and (iii)
whether baseline levels of these hormones predict incident
sarcopenia defined by low muscle mass alone as well as by
low muscle mass and function.
Materials and methods
Subjects
Men aged 40–79 years were recruited from population regis-
ters in Manchester, UK, and Leuven, Belgium, for participa-
tion in the European Male Ageing Study (EMAS). Details
concerning the study design and recruitment have been de-
scribed previously.29 Briefly, in 2003–05, community-dwelling
men were invited to attend by a letter of invitation which
included a postal questionnaire. Those who agreed to partic-
ipate attended a local clinic for an interviewer-assisted ques-
tionnaire and clinical and biological assessments. In 2007–09,
participants were invited to take part in a repeat survey.
Ethical approval for the study was obtained in accordance
with local institutional requirements. All subjects provided
written informed consent.
Study questionnaires and clinical assessments
The postal questionnaire gathered information on smoking
and medical conditions, including heart diseases, high blood
pressure, pituitary disease, testicular disease, chronic bron-
chitis, asthma, peptic ulcer, epilepsy, diabetes, liver condi-
tions, kidney conditions, prostate disease, adrenal disease,
and thyroid disease. The interviewer-assisted questionnaire
asked about current drugs. Height was measured to the
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nearest 1mm using a stadiometer (Leicester Height Measure,
SECA Ltd, UK) and body weight to the nearest 0.1 kg using an
electronic scale (SECA, model no. 8801321009, SECA Ltd, UK).
Physical performance was measured with a component of
the Reuben’s physical performance test [seconds taken to
walk 50 ft (15.24m)],30 with gait speed expressed as metres
per second. Follow-up investigations were performed using
similar assessments after a median interval of 4.3 years
[standard deviation (SD) = 0.6].
Hormonal measurements
A fasting morning venous blood sample was taken at baseline
in all subjects. Measurement of T and E2 was carried out by
gas chromatography–tandem mass spectrometry, and SHBG
was measured by the Modular E170 platform electroche-
miluminescence immunoassay. Free and bioavailable T and
E2 were derived from total hormone, SHBG, and albumin
using previously described mass action equations and
association constants.31 Serum was assayed for PTH and
IGF-1 by chemiluminescence immunoassay. 25OHD was mea-
sured using radioimmunoassay and 1,25(OH)2D3 by liquid
chromatography–tandem mass spectrometry by an in Leuven
developed and validated method.32
Measurement of muscle mass and muscle strength
At baseline and follow-up, subjects had whole-body DXA
scans performed on QDR 4500A Discovery scanners (Hologic
Inc, Bedford, MA, USA), with measurement of appendicular
lean mass (aLM). Scans were analysed using Hologic APEX
4.0 software. DXA-measured aLM is assumed to be a good
indicator of skeletal muscle mass.33 The precision error was
0.57% in Leuven (n = 20) and 0.56% in Manchester (n = 31).
Devices were cross-calibrated with the European Spine
Phantom. Muscle strength was evaluated by measuring grip
strength with the Jamar 1 hand-held dynamometer (TEC
Inc., Clifton, NJ, USA). Maximal grip strength was recorded
as the highest of three measurements at both sides.34 Low
grip strength is related to poor physical performance,
mobility limitations, and disability35,36 and is used as a surro-
gate endpoint for functional performance in several recent
operational definitions of sarcopenia.1,5–8
Definition of sarcopenia
Sarcopenia was defined using three approaches. The first def-
inition was that of Baumgartner et al. who defined sarcopenia
in men as RASM (aLM/height2)≤ 7.26 kg/m2.4 The second was
that of the International Working Group on Sarcopenia
(IWGS), by which men with RASM ≤ 7.23 kg/m2 and gait
speed< 1.0m/s are sarcopenic.5 The third was based on the
definition of the European Working Group on Sarcopenia in
Older People (EWGSOP), by which a person with low muscle
mass has pre-sarcopenia, a person with also low physical per-
formance or low muscle strength has sarcopenia, and a per-
son with all three criteria has severe sarcopenia.1 Since
EWGSOP suggests several cut-offs for these three criteria,
we defined low muscle mass as RASM ≤ 7.26 kg/m2, low phys-
ical performance as gait speed< 0.8m/s, and low muscle
strength as grip strength< 30 kg, as recently published.37
Statistical analysis
Descriptive statistics were used to summarize subject baseline
characteristics, including age, body mass index (BMI),
smoking, number of comorbidities, sex steroids (total, free,
and bioavailable T and E2 and SHBG), IGF-1, 25OHD, 1,25
(OH)2D, and parathyroid hormone (PTH), as well as aLM,
RASM, gait speed, and grip strength. We categorized the num-
ber of comorbidities into 0, 1, and ≥2 comorbidities since few
subjects (4.1%) have ≥3 comorbidities. Differences in aLM,
gait speed, and grip strength between baseline and follow-
up were determined using the paired t-test. Prevalent
sarcopenia by the definition of Baumgartner, IWGS, and
EWGSOP was calculated at baseline and follow-up. Incident
sarcopenia was defined as the prevalence of sarcopenia at
follow-up though not at baseline. Analyses with incident
sarcopenia by EWGSOP also included men with severe
sarcopenia. aLM, gait speed, and grip strength at baseline
and follow-up as well as percentage (%) change per year in
these variables were calculated in men aged 40–79 years
and in four 10-year age bands, both in the whole cohort and
in the two centres separately. Annual % change was calculated
as [(follow-up-baseline)/baseline]*100/time between base-
line and follow-up. The annual % change in aLM, gait speed,
and grip strength per 10-year age band was visually assessed
using bar plots. Linear regression was used to determine the
strength of the association between baseline hormones as
continuous variables and either annual % change in aLM, gait
speed, and grip strength in the whole cohort as well as in men
aged 60–79 years and 70–79 years, separately. The analyses
were adjusted for age, centre, BMI, smoking, and number of
comorbidities at baseline by including these variables in the
multivariable models. The analyses with total T, total E2, and
IGF-1 were also adjusted for SHBG and the analyses with SHBG
for total T or E2. Results were expressed as β-coefficients and
95% confidence intervals (CI). For ease of interpretation and
comparison, we standardized the independent variables into
z-scores. The hormones were also categorized into quintiles
and 25OHD in <10, 10–20, and ≥20 ng/mL. We also catego-
rized individuals as normal or hypogonadal (total T< 8 or
< 11 nmol/L or free T< 220 pmol/L38). When a significant dif-
ference had been observed in change in aLM, gait speed, or
grip strength between Leuven and Manchester, analyses were
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repeated in the centres separately. We used logistic regression
to determine the associations between baseline hormones
and the risk of incident sarcopenia by the three definitions,
with results expressed as odds ratios (OR) and 95%CI. These
analyses were performed in the whole cohort and in men aged
60–79 years. Results were adjusted for potential confounders.
Statistics were performed using STATA 11.2.
Results
Subjects
Of the 716 men who participated in the baseline and follow-
up survey, 198 men were excluded because of missing aLM or
RASM data or because they were taking musculoskeletal
active therapies (calcium, vitamin D, bisphosphonates, or
glucocorticoids), leaving 518 subjects in the main analysis,
of whom 255 were ≥60 years. Twelve persons with missing
gait speed and 73 persons with missing grip strength were
also excluded, leaving 506 men in the analysis with gait speed
and the IWGS definition of sarcopenia and 433 men in the
analysis with grip strength and the EWGSOP definition of
sarcopenia, respectively. Mean age of the 518 subjects was
60.0 (SD = 10.3) years and BMI 27.2 (SD = 3.7) kg/m2 (Table 1).
Incidence of sarcopenia
Based on the Baumgartner definition of sarcopenia, 76.3%
(n = 395) had no prevalent sarcopenia at baseline and follow-
up, while 8.1% (n = 42) without sarcopenia at baseline devel-
oped sarcopenia at follow-up (‘incident’ sarcopenia) (Table 2).
Of the 506 men in the analysis that defined sarcopenia by
IWGS, 3.0% (n = 15) without prevalent sarcopenia at baseline
became sarcopenic at follow-up. By EWGSOP, 1.4% (n = 6)
developed sarcopenia and 0.2% (n = 1) developed severe
sarcopenia.
Change in appendicular lean mass, gait speed, and
grip strength
Across all age bands, men had a significant mean annual loss
of 0.36% (SD = 1.09) of aLM and 0.15% (SD = 3.20) of gait
speed, while grip strength was not significantly different
(Table 3). Mean annual % loss of aLM was higher in Leuven
than in Manchester [0.46% (SD=1.11) vs. 0.22% (SD=1.03),
P = 0.011; not shown], but annual % change in gait speed
and grip strength were not statistically different between
the centres. Looking at changes per 10-year age bands, aLM
started to decrease in men aged 40–49 years, but the loss
was only significant from age 50 years. Mean annual % loss
of aLM was significantly greater in persons aged 60–69 and
70–79 years as compared with 40–49 years (Figure 1). Men
aged ≥60 years lost gait speed and grip strength, but this was
only significant in the oldest age band (Table 3). Compared
with men aged 40–49 years, who had a stable gait speed and
a significant increase in grip strength, annual % loss of gait
speed was significantly greater in men aged 70–79 years and
annual % loss of grip strength significantly greater in men from
age 60 years (Figure 1).
Baseline hormones and change in appendicular
lean mass, gait speed, and grip strength
Total T was not associated with annual % change in aLM, gait
speed, or grip strength (Table 4). Neither of the two thresh-
old levels of total T for hypogonadism was associated with
higher loss of aLM, gait speed, or grip strength (shown for
Table 1 Subject characteristics at baseline
Variables Mean (SD) n (%)
n=518
Age (years) 60.0 (10.3)
Weight (kg) 83.1 (12.9)
Height (cm) 176.0 (28.9)
BMI (kg/m2) 27.2 (3.7)
Total T (nmol/L) 18.1 (6.0)
Free T (pmol/L) 320.1 (88.7)
Total E2 (pmol/L) 77.2 (25.0)
Free E2 (pmol/L) 1.3 (0.4)
SHBG (nmol/L) 42.4 (19.1)
IGF-1 (ng/mL) 137.1 (39.1)
25OHD (ng/mL) 30.1 (13.2)
1.25(OH)2D (pg/mL) 60.5 (15.5)
PTH (pg/mL) 28.9 (11.2)
Ever smoked (yes vs. no) 306 (59.8)
Number of comorbidities
0 305 (59.6)
1 122 (23.8)
≥2 85 (16.6)
aLM (kg) 24.8 (3.5)
RASM (kg/m2) 8.07 (0.93)
aBaumgartner sarcopenia 81 (15.6)
n=506
Gait speed (m/s) 1.2 (0.2)
bIWGS sarcopenia 12 (2.4)
n=433
Grip strength (kg) 44.3 (8.9)
cEWGSOP sarcopenia 6 (1.3)
cEWGSOP severe sarcopenia 1 (0.2)
Results expressed as mean (SD) and percentage.
aLM, appendicular lean mass; BMI, body mass index; E, oestradiol;
EWGSOP, European Working Group on Sarcopenia in Older People;
IGF-1, insulin-like growth factor-1; IWGS, International Working
Group on Sarcopenia; PTH, parathyroid hormone; RASM, relative
appendicular skeletal muscle mass; SD, standard deviation; SHBG,
sex hormone-binding globulin; T, testosterone; 1.25(OH)2D, 1,25-
dihydroxyvitamin D; 25OHD, 25-hydroxyvitamin D.
aBaumgartner sarcopenia= RASM ≤ 7.26 kg/m2.4
bIWGS sarcopenia= RASM ≤ 7.23 kg/m2+gait speed< 1.0m/s.5
cEWGSOP sarcopenia=RASM ≤7.26 kg/m2+gait speed <0.8m/s or
grip strength <30 kg; severe sarcopenia=RASM ≤7.26 kg/m2+gait
speed<0.8m/s+grip strength<30kg.1
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cut-off at 8 nmol/L). Free T was positively associated with an-
nual % change in grip strength, and men with free T below
the threshold for hypogonadism had a greater decrease in
gait speed and grip strength as compared with persons with
free T above this threshold, however these results became
non-significant after adjustment for age, centre, BMI,
smoking, and number of comorbidities. Total E2 was
Table 2 Number of subjects with sarcopenia at baseline and follow-up
FOLLOW UP, N (%)
No sarcopenia Sarcopenia
aBaumgartner sarcopenia (N=518)
BASELINE, N (%)
No sarcopenia 395 (76.3) 42 (8.1)
Sarcopenia 16 (3.1) 65 (12.5)
bIWGS sarcopenia (N=506)
BASELINE, N (%)
No sarcopenia 479 (94.7) 15 (3.0)
Sarcopenia 4 (0.8) 8 (1.6)
FOLLOW UP, N (%)
No
sarcopenia
Pre-
sarcopenia Sarcopenia
Severe
sarcopenia
cEWGSOP sarcopenia (N=433)
BASELINE, N (%)
No sarcopenia 334 (77.1) 30 (6.9) 5 (1.2) 0 (0)
Pre-sarcopenia 13 (3.0) 42 (9.7) 1 (0.2) 1 (0.2)
Sarcopenia 1 (0.2) 1 (0.2) 4 (0.9) 0 (0)
Severe sarcopenia 0 (0) 0 (0) 0 (0) 1 (0.2)
EWGSOP, European Working Group on Sarcopenia in Older People;
IWGS, International Working Group on Sarcopenia; RASM, relative
appendicular skeletal muscle mass.
aBaumgartner sarcopenia= RASM ≤ 7.26 kg/m2.4
bIWGS sarcopenia= RASM ≤ 7.23 kg/m2+gait speed< 1.0m/s.5
cEWGSOP pre-sarcopenia=RASM≤ 7.26 kg/m2; sarcopenia=RASM
≤ 7.26 kg/m2+gait speed< 0.8m/s or grip strength< 30 kg; severe
sarcopenia=RASM≤ 7.26kg/m2+gait speed< 0.8m/s+grip strength
< 30kg1.
Percentages of subjects with incident sarcopenia or severe
sarcopenia are marked in bold.
Table 3 Appendicular lean mass (aLM), gait speed, and grip strength at
baseline (B) and follow-up (FU) and % change per year
Baseline Follow-up % change/yeara
aLM kg %/year
40–49 26.6 (3.7) 26.5 (3.7) 0.03 (0.94)
50–59 25.3 (3.3) 25.0 (3.3)*** 0.29 (0.99)
60–69 24.3 (3.2) 23.6 (3.2)*** 0.57 (1.12)
70–79 22.9 (2.6) 22.4 (2.6)*** 0.53 (1.20)
40–79 24.8 (3.5) 24.4 (3.5)*** 0.36 (1.09)
Gait speed m/s %/year
40–49 1.26 (0.15) 1.27 (0.15) 0.36 (2.88)
50–59 1.18 (0.16) 1.18 (0.18) 0.23 (3.22)
60–69 1.14 (0.17) 1.12 (0.17) 0.09 (3.07)
70–79 1.10 (0.18) 1.04 (0.18)*** 1.24 (3.35)
40–79 1.17 (0.17) 1.16 (0.19)* 0.15 (3.20)
Grip strength kg %/year
40–49 48.2 (8.0) 49.9 (8.5)** 0.92 (2.93)
50–59 46.4 (8.9) 47.1 (8.8) 0.70 (3.73)
60–69 43.8 (7.6) 42.9 (8.3) 0.34 (3.23)
70–79 38.2 (7.6) 36.1 (8.1)*** 1.18 (3.15)
40–79 44.3 (8.9) 44.2 (9.8) 0.06 (3.41)
Results expressed as mean [standard deviation (SD)].
P-value for the difference between B and FU calculated using t-test.
a% change per year= ([FU–B]/B)*100/time between B and FU.
*P< 0.05. **P< 0.01. ***P< 0.001.
Figure 1 Annual % change in appendicular lean mass, gait speed, and
grip strength by 10-year age band.
40-49 year is referent;*p< 0.05,**p< 0.01,***p< 0.001
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negatively associated with change in aLM, with an annual
0.104% greater decrease in aLM per SD increase in total
E2, and this association remained significant after adjust-
ment for age, centre, BMI, smoking and number of comor-
bidities, and also after further adjustment for SHBG. Free
E2 was negatively associated with change in aLM, but only
after adjustment for confounders. Results for bioavailable T
and E2 were comparable with those for free T and E2 (not
shown). Each SD increase in SHBG was associated with a
greater decrease in aLM, but not after adjustment for con-
founders. No significant associations were observed between
T, E2, and SHBG and change in aLM, gait speed, or grip
strength in men aged 60–79 or 70–79 years separately (not
shown). In men ≥70 years, IGF-1 was positively associated
with change in gait speed, with an annual 0.773% greater de-
crease in gait speed per SD decrease in IGF-1 after adjust-
ment for age, centre, BMI, smoking, and number of
comorbidities. This association remained significant after
further adjustment for SHBG. In men aged 40–79 years, a
positive association was also observed between IGF-1 and
aLM, but after adjustment, this association only remained
significant in subjects from Leuven, where mean annual %
aLM loss was significantly greater than in Manchester
(β = 0.146; 95%CI 0.023,0.269; P = 0.020).
25-hydroxyvitamin D and PTH were not associated with
change in aLM, gait speed, or grip strength, nor as continuous
variables (Table 4) nor in quintiles (not shown). When 25OHD
was categorized in <10, 10–20, and ≥20 ng/mL, men with
25OHD< 10 ng/mL had a greater increase in grip strength
as compared with men with ≥20 ng/mL, but this result be-
came not significant after adjustment for age, centre, BMI,
smoking, and number of comorbidities. When 1,25(OH)2D
was categorized into quintiles, men with 1,25(OH)2D in the
highest quintile had an annual 1.679% greater decrease in
grip strength than men with 1,25(OH)2D in the lowest
quintile, but also this association became not significant after
adjustment for confounders. No significant associations were
observed between 25OHD, 1,25(OH)2D, and PTH and change
in aLM, gait speed, or grip strength in men aged 60–79 or
70–79 years, separately (not shown).
Prediction of incident sarcopenia
Logistic regression was used to determine the association be-
tween baseline hormones and incident sarcopenia by the
three definitions. With the outcome defined as sarcopenia
by Baumgartner (RASM≤ 7.26 kg/m2), no associations were
observed (not shown). With IWGS sarcopenia as the outcome
(RASM≤ 7.23 kg/m2 and gait speed< 1.0m/s), higher base-
line levels of SHBG and 25OHD increased the odds of
sarcopenia by 78% and 80%, respectively, but these results
became non-significant after adjustment for age, centre,
BMI, smoking, and number of comorbidities (Table 5). The
odds of sarcopenia by EWGSOP (RASM ≤ 7.26 kg/m2, gait
speed< 0.8m/s, and/or grip strength< 30kg) increased with
higher baseline levels of 25OHD and decreased with higher
baseline levels of free T and IGF-1, but also these results be-
came non-significant after adjustment for confounders. Re-
sults were comparable in men aged 60–79 years separately
(not shown).
Discussion
In this prospective study, aLM significantly decreased in Euro-
pean men from age 50 years, while gait speed and grip
strength significantly decreased after the seventh decade.
The incidence of sarcopenia by the definitions of
Baumgartner, IWGS, and EWGSOP was 8.1%, 3.0%, and
1.6%, respectively, over a follow-up of 4.3 years. After adjust-
ment for age, centre, BMI, smoking, and number of comor-
bidities at baseline, baseline levels of T and vitamin D
metabolites were not associated with change in aLM, gait
speed, and/or grip strength. A high baseline level of total E2
was associated with a greater decrease in aLM, while low
baseline IGF-1 correlated with a greater decrease in gait
speed in men aged ≥70 years and a greater decrease in aLM
in men aged 40–79 years from Leuven. Baseline endocrine
variables were not independently associated with an in-
creased risk of incident sarcopenia by any definition.
In men aged 40–79 years, we observed a significant mean
annual loss of 0.36% of aLM and 0.15% of gait speed, and a
non-significant mean annual gain of 0.06% of grip strength
over a 4.3-year follow-up. Men aged 70–79 years lost on
average 0.53% of aLM per year. Changes in body composition
with DXA in elderly men have been reported previously, with,
over 2 years, aLM losses from 0.8% to 2.77% in men aged
≥70 years.10,11 In middle-aged men changes in body composi-
tion have been less well investigated. We observed a signifi-
cant decrease in aLM from age 50years and older, with an
annual 0.29% decrease inmen aged 50–59years. This is compa-
rable with a prospective study in 40- to-79-year-old Japanese
men, in whom a significant decrease of leg LM (1.3% over
6 years) was observed in men in their 50s.12 Notwithstanding,
in this and our study, the decrease in LM was more marked in
the elderly. We are not aware of other studies that have re-
ported longitudinal changes in body composition measured
with DXA in middle-aged (and elderly) European men.
Grip strength significantly increased up to age 40–49 years
and then remained stable. A decline did not start until the
seventh decade and the loss only became significant in
men aged 70–79 years. In another longitudinal study that ex-
amined the change in grip strength in middle-aged and el-
derly men, grip strength increased up to age 40 years and
immediately started to decrease thereafter, although 30%
of the subjects aged 40–59 years and 15% of the subjects
Endocrine determinants of incident sarcopenia in European men 7
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aged ≥60 years did not lose grip strength.14 Thus, we con-
clude from this and our study that, after an increase until
the age of 40–49 years, grip strength remains stable in at
least a part of middle-aged persons before it starts to
decrease. At age 70 years, when the annual % decline of grip
strength became significant in our study, this loss was higher
than that of aLM. Longitudinal changes in muscle strength
have indeed been reported to be greater than changes in
muscle mass, probably due to concomitant declines in
neuromuscular control.11 In the Health ABC study, for exam-
ple, the annual leg strength decline was three times greater
than the rate of decline of leg LM.11 The annual 1.18%
decrease in grip strength we observed in men ≥70 years old
is smaller than in men with a mean age of 74.9 years from
LASA (13.2%/3 years) and slightly smaller than in men with
a mean age of 73.7 years from Health ABC (5.8%/3 years).20
As in EMAS, participants in Health ABC are well-functioning
elderly men, while LASA includes frail elderly, which may
account for the greater decline in grip strength.
Similarly to grip strength, gait speed started to decrease in
men of ≥60 years, and the loss was significant in the oldest
age band. Gait speed < 1 and < 0.8m/s has been reported
to predict mortality and adverse outcomes, respectively.39
In our study, however, even in the oldest men, mean gait
speed at follow-up was ≥1.0m/s.
Total, free, and bioavailable T were not associated with
change in aLM, gait speed, or grip strength. The lack of
association between low T and loss of grip strength is in
agreement with other prospective studies,17,19–21 and the
failure to show an association between low T and a greater
decline in physical performance is consistent with findings
in some but not in all cohorts.17,20 In MINOS and MrOS, low
levels of T were associated with more loss of muscle
mass.17,18 How can we explain the lack of association
between T and change in muscle parameters in our cohort?
The mean age of our study participants was 60.0 years, while
this ranged from 68.0 to 74.9 years in other male co-
horts.17,18,20 As mentioned earlier, a significant decrease in
gait speed and grip strength occurred after the seventh de-
cade and the greatest decrease in aLM also occurred in
men ≥60 years. Moreover, most participants had T levels
within the normal range, as the prevalence of hypogonadism,
defined by total T< 8 nmol/L, total T< 11 nmol/L, or free
T< 220 pmol/L,38 was 1.8%, 10.3%, and 13.2%, respectively
(not shown). Thus, the relatively young age, low prevalence
of hypogonadism, and the small power for subanalyses in
elderly individuals might explain why we did not find an asso-
ciation between T and change in muscle mass, gait speed, or
grip strength.
There are few published data about the role of E2 in the
preservation of muscle mass and function. Androgens might
convert into oestrogens through aromatization and activate
the oestrogen receptors or oestrogens might have an inde-
pendent effect. However, T alone and not its aromatizationTa
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into E2 seems responsible for the anabolic effect of T on
muscle mass in men since T replacement therapy
was equally efficacious when co-administered with an
aromatase-inhibitor, which inhibits the conversion into E2.
40
We found a negative association between total E2 and
change in aLM, which persisted after adjustment, meaning
that a higher baseline level of E2 was associated with a
greater decrease in aLM. No other significant associations
were observed between total, free, or bioavailable E2 and
change in gait speed or grip strength. The longitudinal asso-
ciation between E2 and change in muscle parameters has
been scantily investigated, with only two prospective studies
including a follow-up period from 2 to 4.5 years.17,21 In these
studies, neither total nor bioavailable E2 was associated with
change in muscle mass, muscle strength, or physical perfor-
mance, which is in contrast with our observation of a nega-
tive association between E2 and change in aLM. Most cross-
sectional studies found no or a positive association between
E2 and muscle mass and/or muscle strength,
41 although we
are aware of two cross-sectional studies that showed a neg-
ative association between E2 and muscle strength.
42,43 A
negative effect of E2 on muscle is hard to explain. Factors
which have not been adjusted for may account for this asso-
ciation. SHBG was not associated with change in muscle
mass, strength, or physical performance, which is in agree-
ment with other prospective studies.19 In MrOS, however,
higher SHBG was associated with less loss of muscle mass
and strength, although not independently of sex hor-
mones.17 Ageing is also associated with a progressive decline
of IGF-1 and a decreased response of cells to IGF-1. We
found that in persons ≥70 years, low baseline IGF-1 was pos-
itively associated with a higher decrease in gait speed, which
is in agreement with cross-sectional studies.44 Since IGF-1
might influence SHBG, this result was adjusted for SBHG,
but it remained significant, suggesting an independent effect
of IGF-1.
We did not find a significant association between 25OHD
and change in aLM, gait speed, or grip strength. Some studies
have however shown an association between low 25OHD and
loss of muscle strength22,24 or a decline in physical perfor-
mance.23 In other studies no association with muscle
mass,22,24 muscle strength,25 or physical performance was
observed.25,26 A reason why we may not have been able to
show these associations is the relatively high mean level of
25OHD in our cohort (30.1 ng/mL). There currently is no
consensus about which level of 25OHD defines the threshold
for optimal (extra) skeletal health, but since mean 25OHD in
our cohort exceeds the levels suggested by the Institute of
Medicine (20mg/dL) and the Endocrine Society Task Force
(30 ng/mL),45 this might explain the lack of association be-
tween 25OHD and muscle function. However, even in men
with 25OHD in the lowest quintile (<18.7 ng/mL) or
<10 ng/mL, no significant association with muscle parame-
ters was observed. As it is possible that 25OHD not accurately
reflects the action of 1,25(OH)2D, we also examined the asso-
ciation with 1,25(OH)2D and found no association with
change in aLM, gait speed, or grip strength after adjustment
for age, centre, BMI, smoking, and number of comorbidities.
This is in accordance with some,46 but not all cross-sectional
studies,47,48 where positive associations were reported be-
tween 1,25(OH)2D and muscle mass, strength, or physcial
performance. Finally, the effect of PTH was investigated as
it has been suggested that hyperparathyroidism, secondary
to low vitamin D, mediates the effect of 25OHD and may also
have a direct negative effect on muscle.22 However, PTH,
even the highest quintile, was not associated with changes
in aLM, gait speed, or grip strength. Others found that high
PTH was associated with a greater decline in muscle mass
or grip strength18,22 or with a non-significantly faster decline
in grip strength and walking speed.49
Over a mean follow-up of 4.3 years, 8.1% developed
sarcopenia by the definition of Baumgartner. With the more
stringent definitions of IWGS and EWGSOP, this number de-
creased to 3.0% and 1.6%, respectively. Most people did
not transition from their original state of aLM, gait speed,
and grip strength, and only few people developed sarcopenia,
suggesting that 4.3 years may not have been long enough for
aLM, gait speed, and/or grip strength to decrease below their
respective sarcopenia threshold. However, in a prospective
cohort of almost 3000 initially well-functioning elderly aged
between 70 and 79 years, only 7% transitioned from pre-
sarcopenia to sarcopenia, while no one transitioned from
normal to sarcopenia, and this over a 9-year follow-up.50 Hor-
mones were poor predictors of incident sarcopenia, even in
men aged 60–79 years. While none of these predicted the risk
of RASM≤ 7.26 kg/m2 only, the risk of IWGS sarcopenia, de-
fined as low RASM and low gait speed, was predicted by high
baseline SHBG or 25OHD, but not after adjustment. After ad-
justment for age, centre, BMI, smoking, and number of co-
morbidities, the risk of EWGSOP sarcopenia, defined as low
RASM plus low gait speed and/or low grip strength, was not
predicted by baseline levels of T, E2, SHBG, IGF-1, 25OHD,
1,25(OH)2D, or PTH, though the number of men with
sarcopenia was small (n = 7).
Our study used standard methods with repeat measure-
ments over 4.3 years. However, some limitations need to be
taken into account. Firstly, the follow-up rate was 84.5%. It
is possible that those who did not attend for the follow-up sur-
vey may have been more (or less) likely to have developed
sarcopenia than those who attended, and so some caution is
required in interpreting the incidence data. However, any fac-
tors influencing non-participation are unlikely to have influ-
enced the associations between baseline hormones and
outcome, as these were based on an internal comparison of
participants. Secondly, our analysis was based on a baseline
assessment of hormones and cannot exclude any effect of
change in hormone levels on change in muscle mass, gait
speed, or grip strength, for which repeat measurements are
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required. Finally, due to the young age of our cohort and short
time of follow-up, the incidence of sarcopenia was low. This
would limit the power to detect true biological associations
between hormones and incident sarcopenia.
In conclusion, in middle-aged and elderly European men,
aLM significantly decreased from age 50 years, while gait
speed and grip strength significantly decreased after the sev-
enth decade. No consistent associations were observed
between baseline endocrine variables, especially T and
25OHD, and change in muscle mass, gait speed, or grip
strength. In men aged ≥70 years, low baseline IGF-1 was asso-
ciated with a greater decrease in gait speed. Randomized tri-
als remain necessary to prove definitively whether T, vitamin
D, or IGF-1 replacement is useful to promote maintenance of
muscle mass and function and prevention of sarcopenia in
ageing men.
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